Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellSource CoTSE:4880 -0.29%69 PE Ratio (TTM) is 96.07 as of Jul. 17, 2026, which is 13% above its 10-year median of 85.03. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円780.80 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 270 Biotechnology companies, CellSource Co ranks worse than 83.7% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-17), CellSource Co's share price is
円342.00.
CellSource Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was 円3.56. Therefore, CellSource Co's PE Ratio (TTM) for today is 96.07.
The historical rank and industry rank for CellSource Co's PE Ratio (TTM) or its related term are showing as below:
TSE:4880'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 23.78 Med: 85.03 Max: 957.41
Current: 96.07
During the past 9 years, the highest PE Ratio (TTM) of CellSource Co was 957.41. The lowest was 23.78. And the median was 85.03.
TSE:4880's PE Ratio (TTM) is ranked worse than 83.7% of 270
companies
in the Biotechnology industry
Industry Median: 27.27
vs TSE:4880: 96.07
During the past 3 years, the average EPS without NRIGrowth Rate was -72.80% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -38.30% per year.
During the past 9 years, CellSource Co's highest 3-Year average EPS without NRI Growth Rate was 51.70% per year. The lowest was -72.80% per year. And the median was 31.10% per year.
CellSource Co's EPS (Basic) for the
six
months ended in Apr. 2026 was 円3.59.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 was 円3.57.
CellSource Co (TSE:4880) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
CellSource Co PE Ratio (TTM) Related Terms
CellSource Co PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for CellSource Co's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, ALNY: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, CellSource Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where CellSource Co's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
CellSource Co's PE Ratio (TTM) for today is calculated as
CellSource Co's Share Price of today is 円342.00.
For company reported semi-annually, CellSource Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円3.56.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
CellSource Co (TSE:4880) has a PE Ratio (TTM) of 96.07 as of Jul. 17, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on CellSource Co and its competitors. This is 13% above median its historical median of 85.03. Over the past decade, CellSource Co's PE Ratio (TTM) has ranged from 23.78 to 957.41. According to the industry distribution chart, CellSource Co ranks #226 out of 270 companies in the Biotechnology industry, placing it in the top 83.7%.
Is CellSource Co's PE Ratio (TTM) too high?
CellSource Co's current PE Ratio (TTM) of 96.07 is 13% above median its 10-year median of 85.03. Over the past 10 years, this metric has ranged from a low of 23.78 to a high of 957.41. The Biotechnology industry median PE Ratio (TTM) is 27.27. CellSource Co's value of 96.07 is 252.3% above this industry median. Based on the distribution chart, CellSource Co ranks #226 out of 270 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's PE Ratio (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #226 out of 270 companies for PE Ratio (TTM). This places CellSource Co in the lower half of its industry. The industry median PE Ratio (TTM) is 27.27. CellSource Co's value of 96.07 is 252.3% above this benchmark. Historically, CellSource Co's own PE Ratio (TTM) has ranged from 23.78 to 957.41 over the past decade. While the company's 10-year median is 85.03 vs. the industry median of 27.27, CellSource Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 27.27, based on 270 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current PE Ratio (TTM) of 96.07 is 252.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on CellSource Co and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 27.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current PE Ratio (TTM) is 96.07, which is 13% above median its own 10-year median of 85.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円780.80, compared to a current price of 円342.00 — trading 56.2% below its estimated fair value. The current PE Ratio (TTM) is 96.07, which is 13% above median its 10-year median of 85.03 and 252.3% above the Biotechnology industry median of 27.27. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current PE Ratio (TTM) is 96.07 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円342.00 is trading 56.2% below its estimated GF Value™ of 円780.80.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
PE Ratio (TTM): 96.07 (13% above median its 10-year median of 85.03)
GF Value™: 円780.80 vs. price of 円342.00 (56.2% below fair value)
Industry Position: 252.3% above the Biotechnology median (#226 of 270)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
